000128945 001__ 128945
000128945 005__ 20240228143359.0
000128945 0247_ $$2doi$$a10.1038/leu.2015.319
000128945 0247_ $$2pmid$$apmid:26582644
000128945 0247_ $$2ISSN$$a0887-6924
000128945 0247_ $$2ISSN$$a1476-5551
000128945 0247_ $$2altmetric$$aaltmetric:4809662
000128945 037__ $$aDKFZ-2017-04957
000128945 041__ $$aeng
000128945 082__ $$a610
000128945 1001_ $$aKordes, M.$$b0
000128945 245__ $$aCooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
000128945 260__ $$aBasingstoke$$bNature Publ. Group$$c2016
000128945 3367_ $$2DRIVER$$aarticle
000128945 3367_ $$2DataCite$$aOutput Types/Journal article
000128945 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524483381_2937
000128945 3367_ $$2BibTeX$$aARTICLE
000128945 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128945 3367_ $$00$$2EndNote$$aJournal Article
000128945 520__ $$aActivating BRAF mutations, in particular V600E/K, drive many cancers and are considered mutually exclusive with mutant RAS, whereas inactivating BRAF mutations in the D(594)F(595)G(596) motif cooperate with RAS via paradoxical MEK/ERK activation. Due to the increasing use of comprehensive tumor genomic profiling, many non-V600 BRAF mutations are being detected whose functional consequences and therapeutic actionability are often unknown. We investigated an atypical BRAF mutation, F595L, which was identified along with mutant HRAS in histiocytic sarcoma and also occurs in epithelial cancers, melanoma and neuroblastoma, and determined its interaction with mutant RAS. Unlike other DFG motif mutants, BRAF(F595L) is a gain-of-function variant with intermediate activity that does not act paradoxically, but nevertheless cooperates with mutant RAS to promote oncogenic signaling, which is efficiently blocked by pan-RAF and MEK inhibitors. Mutation data from patients and cell lines show that BRAF(F595L), as well as other intermediate-activity BRAF mutations, frequently coincide with mutant RAS in various cancers. These data define a distinct class of activating BRAF mutations, extend the spectrum of patients with systemic histiocytoses and other malignancies who are candidates for therapeutic blockade of the RAF-MEK-ERK pathway and underscore the value of comprehensive genomic testing for uncovering the vulnerabilities of individual tumors.
000128945 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000128945 588__ $$aDataset connected to CrossRef, PubMed,
000128945 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000128945 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aBRAF protein, human
000128945 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aProto-Oncogene Proteins B-raf
000128945 650_7 $$0EC 3.6.5.2$$2NLM Chemicals$$aHRAS protein, human
000128945 650_7 $$0EC 3.6.5.2$$2NLM Chemicals$$aProto-Oncogene Proteins p21(ras)
000128945 7001_ $$aRöring, M.$$b1
000128945 7001_ $$0P:(DE-He78)1464357f7ec5faf677a390a414e50c88$$aHeining, C.$$b2$$udkfz
000128945 7001_ $$aBraun, S.$$b3
000128945 7001_ $$0P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0$$aHutter, B.$$b4$$udkfz
000128945 7001_ $$0P:(DE-He78)29306fd3ae9f1a9839ed888ebc5c8074$$aRichter, D.$$b5$$udkfz
000128945 7001_ $$0P:(DE-He78)3f888debb126ff36634df058ccaaf2b4$$aGeörg, C.$$b6$$udkfz
000128945 7001_ $$0P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250$$aScholl, C.$$b7$$udkfz
000128945 7001_ $$0P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aGröschel, S.$$b8$$udkfz
000128945 7001_ $$0P:(DE-He78)6c54d919bb3371b6d7f277e2c6262a4a$$aRoth, W.$$b9$$udkfz
000128945 7001_ $$aRosenwald, A.$$b10
000128945 7001_ $$aGeissinger, E.$$b11
000128945 7001_ $$0P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de$$avon Kalle, C.$$b12$$udkfz
000128945 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, D.$$b13$$udkfz
000128945 7001_ $$0P:(DE-He78)fc949170377b58098e46141d95c72661$$aBrors, B.$$b14$$udkfz
000128945 7001_ $$aWeichert, W.$$b15
000128945 7001_ $$aGrüllich, C.$$b16
000128945 7001_ $$0P:(DE-He78)157277fe62f07df1732f9d126a51d1b9$$aGlimm, H.$$b17$$udkfz
000128945 7001_ $$aBrummer, T.$$b18
000128945 7001_ $$0P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aFröhling, Stefan$$b19$$eLast author$$udkfz
000128945 773__ $$0PERI:(DE-600)2008023-2$$a10.1038/leu.2015.319$$gVol. 30, no. 4, p. 937 - 946$$n4$$p937 - 946$$tLeukemia$$v30$$x1476-5551$$y2016
000128945 909CO $$ooai:inrepo02.dkfz.de:128945$$pVDB
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1464357f7ec5faf677a390a414e50c88$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)135e8c8d1dd1b66b8127c3d1e3a9b6a0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)29306fd3ae9f1a9839ed888ebc5c8074$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3f888debb126ff36634df058ccaaf2b4$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2c1a21d1cf5fdc9e297512c9d1354250$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5120a331b1c28045c8ca6a8b1c73c95f$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c54d919bb3371b6d7f277e2c6262a4a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5bacb661d5d7c0220d8f996d980ad8de$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fc949170377b58098e46141d95c72661$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)157277fe62f07df1732f9d126a51d1b9$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000128945 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0144d171d26dbedb67c9db1df35629d$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000128945 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000128945 9141_ $$y2016
000128945 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128945 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128945 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLEUKEMIA : 2015
000128945 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128945 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128945 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128945 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128945 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128945 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128945 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128945 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128945 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128945 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bLEUKEMIA : 2015
000128945 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x0
000128945 9201_ $$0I:(DE-He78)G200-20160331$$kG200$$lAngewandte Bioinformatik$$x1
000128945 9201_ $$0I:(DE-He78)G102-20160331$$kG102$$lAngewandte Funktionelle Genomik$$x2
000128945 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x3
000128945 9201_ $$0I:(DE-He78)G150-20160331$$kG150$$lMolekulare Tumorpathologie$$x4
000128945 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x5
000128945 9201_ $$0I:(DE-He78)L601-20160331$$kL601$$lDKTK Freiburg$$x6
000128945 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x7
000128945 9201_ $$0I:(DE-He78)G240-20160331$$kG240$$lMolekulare Leukämogenese$$x8
000128945 980__ $$ajournal
000128945 980__ $$aVDB
000128945 980__ $$aI:(DE-He78)G100-20160331
000128945 980__ $$aI:(DE-He78)G200-20160331
000128945 980__ $$aI:(DE-He78)G102-20160331
000128945 980__ $$aI:(DE-He78)G010-20160331
000128945 980__ $$aI:(DE-He78)G150-20160331
000128945 980__ $$aI:(DE-He78)L101-20160331
000128945 980__ $$aI:(DE-He78)L601-20160331
000128945 980__ $$aI:(DE-He78)D120-20160331
000128945 980__ $$aI:(DE-He78)G240-20160331
000128945 980__ $$aUNRESTRICTED